106 related articles for article (PubMed ID: 19636702)
1. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
[TBL] [Abstract][Full Text] [Related]
2. Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
Mavroudis D; Saloustros E; Boukovinas I; Papakotoulas P; Kakolyris S; Ziras N; Christophylakis C; Kentepozidis N; Fountzilas G; Rigas G; Varthalitis I; Kalbakis K; Agelaki S; Hatzidaki D; Georgoulias V
Br J Cancer; 2017 Jul; 117(2):164-170. PubMed ID: 28641315
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
Vici P; Brandi M; Giotta F; Foggi P; Schittulli F; Di Lauro L; Gebbia N; Massidda B; Filippelli G; Giannarelli D; Di Benedetto A; Mottolese M; Colucci G; Lopez M
Ann Oncol; 2012 May; 23(5):1121-1129. PubMed ID: 21965475
[TBL] [Abstract][Full Text] [Related]
4. Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
Janni W; Harbeck N; Rack B; Augustin D; Jueckstock J; Wischnik A; Annecke K; Scholz C; Huober J; Zwingers T; Friedl TW; Kiechle M
Br J Cancer; 2016 Apr; 114(8):863-71. PubMed ID: 27031854
[TBL] [Abstract][Full Text] [Related]
5. Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.
Holmes FA; Hellerstedt BA; Pippen JE; Vukelja SJ; Collea RP; Kocs DM; Blum JL; McIntyre KJ; Barve MA; Brooks BD; Osborne CR; Wang Y; Asmar L; O'Shaughnessy J
Cancer Med; 2018 Jun; 7(6):2288-2298. PubMed ID: 29582557
[TBL] [Abstract][Full Text] [Related]
6. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
Goldstein LJ; O'Neill A; Sparano JA; Perez EA; Shulman LN; Martino S; Davidson NE
J Clin Oncol; 2008 Sep; 26(25):4092-9. PubMed ID: 18678836
[TBL] [Abstract][Full Text] [Related]
7. Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.
Kluger N; Jacot W; Frouin E; Rigau V; Poujol S; Dereure O; Guillot B; Romieu G; Bessis D
Ann Oncol; 2012 Nov; 23(11):2879-2884. PubMed ID: 22571858
[TBL] [Abstract][Full Text] [Related]
8. Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.
Coombes RC; Kilburn LS; Tubiana-Mathieu N; Olmos T; Van Bochove A; Perez-Lopez FR; Palmieri C; Stebbing J; Bliss JM
Eur J Cancer; 2016 Jun; 60():146-53. PubMed ID: 27125966
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.
Rahal S; Boher JM; Extra JM; Tarpin C; Charafe-Jauffret E; Lambaudie E; Sabatier R; Thomassin-Piana J; Tallet A; Resbeut M; Houvenaeghel G; Laborde L; Bertucci F; Viens P; Gonçalves A
BMC Cancer; 2015 Oct; 15():697. PubMed ID: 26466893
[TBL] [Abstract][Full Text] [Related]
10. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study.
Mozaffari F; Lindemalm C; Choudhury A; Granstam-Björneklett H; Lekander M; Nilsson B; Ojutkangas ML; Osterborg A; Bergkvist L; Mellstedt H
Cancer Immunol Immunother; 2009 Jan; 58(1):111-20. PubMed ID: 18488220
[TBL] [Abstract][Full Text] [Related]
11. Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.
Fernandes R; Mazzarello S; Stober C; Ibrahim MFK; Dudani S; Perdrizet K; Majeed H; Vandermeer L; Shorr R; Hutton B; Fergusson D; Gyawali B; Clemons M
J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 30241156
[TBL] [Abstract][Full Text] [Related]
12. Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.
Dimitrakopoulos FI; Goussia A; Koliou GA; Dadouli K; Batistatou A; Kourea HP; Bobos M; Arapantoni-Dadioti P; Tzaida O; Koletsa T; Chrisafi S; Sotiropoulou M; Papoudou-Bai A; Nicolaou I; Charchanti A; Mauri D; Aravantinos G; Binas I; Res E; Psyrri A; Pectasides D; Bafaloukos D; Koumarianou A; Bompolaki I; Rigakos G; Karanikiotis C; Koutras A; Zagouri F; Gogas H; Fountzilas G
Breast; 2024 Feb; 73():103668. PubMed ID: 38176305
[TBL] [Abstract][Full Text] [Related]
13. Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.
Wimmer K; Sachet M; Ramos C; Frantal S; Birnleitner H; Brostjan C; Exner R; Filipits M; Bago-Horvath Z; Rudas M; Bartsch R; Gnant M; Singer CF; Balic M; Egle D; Oehler R; Fitzal F
J Exp Clin Cancer Res; 2023 Nov; 42(1):300. PubMed ID: 37957750
[TBL] [Abstract][Full Text] [Related]
14. Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.
Schröder L; Rack B; Sommer H; Koch JG; Weissenbacher T; Janni W; Schneeweiss A; Rezai M; Lorenz R; Jäger B; Schramm A; Häberle L; Fasching PA; Friedl TW; Beckmann MW; Scholz C
Geburtshilfe Frauenheilkd; 2016 May; 76(5):542-550. PubMed ID: 27239063
[No Abstract] [Full Text] [Related]
15. Quantifying Chemotherapy Delivery in Older and Younger Women With Early-Stage Breast Cancer Using Longitudinal Cumulative Dose.
Pak J; Nyrop KA; Muss HB; Forster MK; Lund JL
Oncologist; 2024 Apr; 29(4):311-315. PubMed ID: 38330406
[TBL] [Abstract][Full Text] [Related]
16. Association between Concomitant Use of Hydrochlorothiazide and Adverse Chemotherapy-Related Events among Older Women with Breast Cancer Treated with Cyclophosphamide.
Hsu CD; Hinton SP; Reeder-Hayes KE; Sanoff HK; Lund JL
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):520-523. PubMed ID: 31871107
[TBL] [Abstract][Full Text] [Related]
17. Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy.
Hatse S; Serena M; Vulsteke C; Punie K; Neven P; Smeets A; Laenen A; Wildiers H
Transl Oncol; 2022 Dec; 26():101551. PubMed ID: 36219936
[TBL] [Abstract][Full Text] [Related]
18. Influence of the Sense of Coherence, the Doctor-Patient Relationship, Optimism and Non-Haematological Adverse Reactions on Health-Related Quality of Life in Patients with Breast Cancer.
Prieto-Callejero B; Rivera F; Andrés-Villas M; Gómez-Salgado J
J Clin Med; 2019 Nov; 8(12):. PubMed ID: 31766496
[TBL] [Abstract][Full Text] [Related]
19. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
[TBL] [Abstract][Full Text] [Related]
20. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; Tubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MW; Reise JA; Wilkinson K; Hupperets P
J Clin Oncol; 2011 Aug; 29(24):3247-54. PubMed ID: 21768453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
